Analyst Forecasts Just Became More Bearish On Beam Therapeutics Inc. (NASDAQ:BEAM)

One thing we could say about the analysts on Beam Therapeutics Inc. (NASDAQ:BEAM) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative. At US$27.48, shares are up 6.1% in the past 7 days. It will be interesting to see if this downgrade motivates investors to start selling their holdings.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

After the downgrade, the consensus from Beam Therapeutics' 14 analysts is for revenues of US$49m in 2026, which would reflect a disturbing 69% decline in sales compared to the last year of performance. Losses are supposed to balloon 410% to US$4.42 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$79m and losses of US$4.34 per share in 2026. So there's definitely been a change in sentiment in this update, with the analysts administering a substantial haircut to this year's revenue estimates, while at the same time holding losses per share steady.

Check out our latest analysis for Beam Therapeutics

There was no real change to the consensus price target of US$52.15, suggesting that the revisions to revenue estimates are not expected to have a long-term impact on Beam Therapeutics' valuation.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 90% by the end of 2026. This indicates a significant reduction from annual growth of 20% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 23% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Beam Therapeutics is expected to lag the wider industry.

The Bottom Line

Unfortunately analysts also downgraded their revenue estimates, and industry data suggests that Beam Therapeutics' revenues are expected to grow slower than the wider market. Overall, given the drastic downgrade to this year's forecasts, we'd be feeling a little more wary of Beam Therapeutics going forwards.

Still, the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Beam Therapeutics analysts - going out to 2028, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.